A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2013
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Jan 2012 Actual initiation date Jan 2012 added as reported by ClinicalTrials.gov.
- 25 Jan 2012 Planned end date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.